Consistent responses of the human vascular smooth muscle cell in culture: Implications for restenosis Euan Munro, FRCSEd, Philip Chan, FRCS, Mahendra.

Slides:

Advertisements

Similar presentations

Endothelial cell seeding reduces thrombogenicity of Dacron grafts in humans Per Örtenwall, MD, PhD *, Hans Wadenvik, MD, PhD **, Jack Kutti, MD, PhD **,

Advertisements

The role of arteriovenous shunts in the pathogenesis of varicose veins Howard C. Baron, M.D., Sebastiano Cassaro, M.D. Journal of Vascular Surgery Volume.

The effect of inguinal lymphatic manipulation on regional lymph flow patterns Jeffrey R. Rubin, MD, Lisa B. Eberlin, MD Journal of Vascular Surgery Volume.

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

Acute mesenteric ischemia after cardiopulmonary bypass

A review of 100 consecutive reconstructions of the distal vertebral artery for embolic and hemodynamic disease Ramon Berguer, MD, PhD, Mark D. Morasch,

John Large, F.R.C.S. (Edin.) Journal of Vascular Surgery

Popliteal artery stenosis caused by a Baker's cyst

Heparin-coated catheters and heparin-induced thrombocytopenia

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Sanjeev Sarin, FRCS, John H. Scurr, FRCS, Philip D

Foot volumetry can predict recurrent ulceration after subfascial ligation of perforators and saphenous ligation A.W. Bradbury, BSc, MD, FRCSEd, C.V.

Ultrasound measurement of the luminal diameter of the abdominal aorta and iliac arteries in patients without vascular disease Ole Martin Pedersen, MD,

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

Lloyd M. Taylor, M.D., Edward S. Phinney, M.D., John M. Porter, M.D.

Jian-ming Li, MDa, Charles S. C. Garnette, MDa, Mitchell Cahn, MDa, R

Mycotic axillary artery aneurysm

Mark Wengrovitz, MD. , Lulseged G. Selassie, MD. , Robert R. M

Jeffrey P. Carpenter, MD, John E. Tomaszewski, MD

A new valvulotome for in situ bypass grafts

Smooth muscle cells cultured from human saphenous vein exhibit increased proliferation, invasion, and mitogen-activated protein kinase activation in vitro.

Jeffrey R. Rubin, M.D., James M. Malone, M.D., Jerry Goldstone, M.D.

Flush saphenofemoral ligation and multiple stab phlebectomy preserve a useful greater saphenous vein four years after surgery Louis J. Fligelstone, FRCS,

Malcolm O. Perry, MD, Richard Kempczinski, MD

The proliferative response to platelet-derived growth factor of smooth muscle cells isolated from synthetic vascular grafts in a canine model David J.

Interposition grafting for reoperation on the common femoral artery

Heparin-coated catheters and heparin-induced thrombocytopenia

Milton M. Slocum, MD, John G. Adams, MD, Rosemary Teel, MT, Donald P

Effects of heparin, desmopressin, and isovolemic hemodilution with dextran on thrombus formation in synthetic vessel grafts inserted into the vena cava.

Potential predictors of outcome in patients with tissue loss who undergo infrainguinal vein bypass grafting James M. Seeger, MD, Henry A. Pretus, MD,

Mrinal Saharay, FRCS, David A. Shields, FRCS, John B

Objective tinnitus resulting from internal carotid artery stenosis

Yehuda G. Wolf, MD, Lars M. Rasmussen, MD, Yoav Sherman, MD, Warner P

Refinements in the ultrasonic detection of popliteal vein reflux

Renal artery repair in African-Americans

Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogen-activated protein.

Vein compression by arterial aneurysms

Regarding "Flush saphenofemoral ligation and multiple stab phlebectomy preserve a useful greater saphenous vein four years after surgery" Germano Lucertini,

Functional analysis of cryopreserved veins

Georg Matheis, MD, Friedhelm Beyersdorf, MD

Calvin B. Ernst, MD Journal of Vascular Surgery

James R. Burnett, MB, BS, FRACS, Robert J. Lusby, MD, FRCS, FRACS

Results of six hundred thirty-six esophageal transections with paraesophagogastric devascularization in the treatment of esophageal varices Mitsuo Sugiura,

Iatrogenic superior mesenteric arteriovenous fistula

Cardiovascular surgery—The rocket and its stars: Presidential address

The fate of the donor artery in extraanatomic revascularization

Composite sequential bypasses to the ankle and beyond for limb salvage

Renovascular operations in patients with chronic renal insufficiency: Do the benefits justify the risks? John W. Hallett, M.D., Richard Fowl, M.D., Peter.

Research and research funding in vascular surgery

Regarding “Venous ulcers and the superficial venous system”

R. T. A. Chalmers, MB, ChB, FRCSE, A. Y. Synn, MD, J. J

J.Dennis Baker, MD Journal of Vascular Surgery

James E. Edwards, MD, Lloyd M. Taylor, MD, John M. Porter, MD

Polytetrafluoroethylene versus human umbilical vein in above-knee femoropopliteal bypass: Six-year results of a randomized clinical trial Gijs J. Aalders,

Early experience with cryopreserved saphenous vein allografts as a conduit for complex limb-salvage procedures Philip J. Walker, FRACS, R.Scott Mitchell,

Should patient age be a consideration in carotid endarterectomy?

The effects of endothelial injury on smooth muscle cell proliferation

Monitoring vascular surgical performance

Homologous veins as an arterial substitute: Long-term results

D. Emerick Szilagyi, MD—An appreciation

Presidential address: The second-generation vascular surgeon

George D. Lilly 1906–1988 Journal of Vascular Surgery

James A. DeWeese, MD Journal of Vascular Surgery

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Innominate artery trauma: A thirty-year experience

Popliteal entrapment syndrome: A report of tibial nerve entrapment

John Large, F.R.C.S. (Edin.) Journal of Vascular Surgery

Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia—A review Alexander W. Clowes, MD, Michael A. Reidy,

Lessons learned in adopting the in situ saphenous vein bypass

Cornelius A. Sullivan, MD, Michael J. Rohrer, MD, Bruce S. Cutler, MD

Presentation transcript:

Consistent responses of the human vascular smooth muscle cell in culture: Implications for restenosis Euan Munro, FRCSEd, Philip Chan, FRCS, Mahendra Patel, PhD, Laura Betteridge, BSc(Hons), Karen Gallagher, BSc(Hons), Michael Schachter, MRCP, Peter Sever, FRCP, John Wolfe, FRCS Journal of Vascular Surgery Volume 20, Issue 3, Pages 482-487 (September 1994) DOI: 10.1016/0741-5214(94)90149-X Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 1 A, Mean (±range) percentage of 14-day proliferation of 15% FCS stimulated VSMC at passage 3 derived from proximal (diagonal bars), middle (unfilled bars), distal (checkered bars), and pooled (filled bars) cultures of saphenous vein from seven patients. Fourteen-day percentage proliferation was calculated by ([cell count at day 14/cell count at day 0] × 100). Variations between cultures were not significantly different from interreplicate variance (experimental error) (ANOVA). VSMC proliferation rates did not differ significantly between individual patients (ANOVA). B, Mean (± range) percentage of 14-day heparin inhibition of proliferation of 15% FCS stimulated VSMC at passage 3 derived from proximal (diagonal bars), middle (unfilled bars), distal (checkered bars), and pooled (filled bars) cultures of saphenous vein from seven patients. Fourteen-day heparin inhibition of proliferation was calculated by ([1 - (cell count of heparin-treated cells at day 14/cell count of control cells at day 14]) × 100. Differences between cultures were not significantly different from interreplicate variance (experimental error) (ANOVA), but see results regarding patient 3. Heparin inhibition was significantly different between individual patients (p = 0.02, ANOVA). Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 1 A, Mean (±range) percentage of 14-day proliferation of 15% FCS stimulated VSMC at passage 3 derived from proximal (diagonal bars), middle (unfilled bars), distal (checkered bars), and pooled (filled bars) cultures of saphenous vein from seven patients. Fourteen-day percentage proliferation was calculated by ([cell count at day 14/cell count at day 0] × 100). Variations between cultures were not significantly different from interreplicate variance (experimental error) (ANOVA). VSMC proliferation rates did not differ significantly between individual patients (ANOVA). B, Mean (± range) percentage of 14-day heparin inhibition of proliferation of 15% FCS stimulated VSMC at passage 3 derived from proximal (diagonal bars), middle (unfilled bars), distal (checkered bars), and pooled (filled bars) cultures of saphenous vein from seven patients. Fourteen-day heparin inhibition of proliferation was calculated by ([1 - (cell count of heparin-treated cells at day 14/cell count of control cells at day 14]) × 100. Differences between cultures were not significantly different from interreplicate variance (experimental error) (ANOVA), but see results regarding patient 3. Heparin inhibition was significantly different between individual patients (p = 0.02, ANOVA). Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 2 Cell number (mean ± range) of 15% FCS stimulated VSMC at passage 3 derived from proximal, middle, distal, and pooled cultures of saphenous vein from single patient over 14 days. Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 3 A, Mean (± range) 14-day percentage proliferation of 15% FCS stimulated VSMC derived from pooled cultures of saphenous vein from six patients at passages 2 or 3 to 6. Fourteen-day percentage proliferation was calculated by ([cell count at day 14/cell count at day 0] × 100). Variations in VSMC proliferation rates at different passages for individual patients were not significantly different from interreplicate variance (experimental error) (ANOVA). B, Mean (± range) 14-day heparin inhibition of proliferation of 15% FCS stimulated VSMC derived from pooled cultures of saphenous vein from six patients at passages 2 or 3 to 6. Fourteen-day heparin inhibition of proliferation was calculated by ([1 - [cell count of heparin treated cells at day 14/cell count of control cells at day 14]) × 100. Variations in heparin inhibition at different passages within each patient were not significantly different from interreplicate variance (experimental error) (ANOVA). Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 3 A, Mean (± range) 14-day percentage proliferation of 15% FCS stimulated VSMC derived from pooled cultures of saphenous vein from six patients at passages 2 or 3 to 6. Fourteen-day percentage proliferation was calculated by ([cell count at day 14/cell count at day 0] × 100). Variations in VSMC proliferation rates at different passages for individual patients were not significantly different from interreplicate variance (experimental error) (ANOVA). B, Mean (± range) 14-day heparin inhibition of proliferation of 15% FCS stimulated VSMC derived from pooled cultures of saphenous vein from six patients at passages 2 or 3 to 6. Fourteen-day heparin inhibition of proliferation was calculated by ([1 - [cell count of heparin treated cells at day 14/cell count of control cells at day 14]) × 100. Variations in heparin inhibition at different passages within each patient were not significantly different from interreplicate variance (experimental error) (ANOVA). Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions

Fig. 4 A, Mean (± range) 14-day percentage proliferation of 15% FCS stimulated VSMC derived from paired artery (filled bars) and saphenous vein (unfilled bars) samples from four patients. Fourteen-day percentage proliferation was calculated by ([cell count at day 14/cell count at day 0] × 100). Variations in proliferation rates between artery and vein samples within each pair were not significantly different from interreplicate variance (experimental error) (ANOVA). B, Mean (± range) 14-day heparin inhibition of proliferation of 15% FCS stimulated VSMC derived from paired artery (filled bars) and saphenous vein (unfilled bars) samples from four patients. Fourteen-day heparin inhibition of proliferation was calculated by (1 - [cell count of heparin treated cells at day 14/cell count of control cells at day 14]) × 100. Variations between heparin inhibitions of artery and vein samples within each pair were not significantly different from interreplicate variance (experimental error) (ANOVA). Journal of Vascular Surgery 1994 20, 482-487DOI: (10.1016/0741-5214(94)90149-X) Copyright © 1994 Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter Terms and Conditions